PTC Therapeutics, Inc. Appoints Manal Morsy, M.D., PH.D. as Vice President of Regulatory Affairs

SOUTH PLAINFIELD, N.J., June 26 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the appointment of Manal Morsy, M.D., Ph.D. as Vice President of Regulatory Affairs. In this role, Dr. Morsy will be responsible for leading PTC's regulatory affairs activities for PTC124, PTC299, and future clinical programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are thrilled to welcome Dr. Morsy to our management team. Her broad experience in leading successful regulatory strategies will be invaluable to PTC as we continue the rapid advancement of our clinical programs," said Stuart Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics. "Dr. Morsy adds critical expertise in the regulatory arena as we expand our capabilities and move toward our goal of becoming a fully integrated biopharmaceutical company."

"I am excited to join the PTC Therapeutics team. The Company's clinical pipeline has tremendous potential to address significant areas of unmet medical need, and I am looking forward to guiding the regulatory strategies to advance the registration and commercialization plans for these novel and potentially life-changing compounds to patients," commented Dr. Morsy.

Prior to joining PTC, Dr. Morsy spent three years at Tibotec / J&J, most recently serving as Senior Director, Global Regulatory Affairs. There she was responsible for global regulatory activities for the company's pediatric development programs and the tuberculosis program. Previous to her tenure at Tibotec, Dr. Morsy served as Director of Worldwide Regulatory Affairs for Merck & Co., where she supported new regulatory filings in the US and abroad, as well as supplemental filings for previously approved products.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, CV Therapeutics and Schering-Plough. For more information, please visit the Company's website at www.ptcbio.com.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comPTC Therapeutics, Inc.

CONTACT: Jane Baj of PTC Therapeutics, Inc., +1-908-222-7000 x167,jbaj@ptcbio.com; or Sheryl Seapy of Pure Communications, +1-949-608-0841,sheryl@purecommunicationsinc.com

Web site: http://www.ptcbio.com//